{
    "clinical_study": {
        "@rank": "43530", 
        "arm_group": [
            {
                "arm_group_label": "CNV2197944", 
                "arm_group_type": "Experimental", 
                "description": "CNV2197944 75mg tid 21 days"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo 1 cap tid 21 days"
            }
        ], 
        "brief_summary": {
            "textblock": "To investigate the effect of repeat oral dosing of CNV2197944 75 mg tid on the pain\n      experienced in diabetic peripheral neuropathy (DPN) as measured by changes in PI-NRS after\n      three weeks of treatment compared to the baseline period."
        }, 
        "brief_title": "Efficacy and Safety of CNV2197944 Versus Placebo in Patients With Diabetic Peripheral Neuropathy", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetic Peripheral Neuropathy", 
        "condition_browse": {
            "mesh_term": [
                "Peripheral Nervous System Diseases", 
                "Demyelinating Diseases", 
                "Polyneuropathies", 
                "Nerve Compression Syndromes", 
                "Neurologic Manifestations", 
                "Neurotoxicity Syndromes", 
                "Diabetic Neuropathies"
            ]
        }, 
        "detailed_description": {
            "textblock": "A 3 week randomised crossover study to investigate the effect of repeat oral dosing of\n      CNV2197944 75 mg tid versus placebo for on the pain experienced in diabetic peripheral\n      neuropathy (DPN). Each 3 week treatment period is seperated by a 2 week washout period. The\n      primary outcome measure is the change from baseline in the PI-NRS after three weeks of\n      treatment. Secondary outcome measures include pain responder rates, clinical and patient\n      global impressions of pain, and the Neuropathic Pain Symptom Inventory."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female between 18 and 85 years of age inclusive, at the time of signing the\n             informed consent\n\n          -  Diabetes Mellitus (Type I or II)with HbA1c <9%\n\n          -  Evidence of symmetrical bilateral pain in lower limbs with evidence of decreased\n             sensation or impaired reflexes and a Michigan Neuropathy Screening -Instrument score\n             of >3 on physical examination\n\n          -  Patients with diabetic peripheral neuropathy (DPN) with pain at screening present for\n             more than 6 months. The maximum duration of DPN will be no longer than 5 years\n\n        Exclusion Criteria:\n\n          -  Patients having other severe pain, which may impair the self-assessment of the pain\n             due to DPN\n\n          -  Patients who have received nerve blocks for neuropathic pain within 4 weeks -Patients\n             on other concomitant medications used to relieve the pain of DPN\n\n          -  Patients with a documented failure to respond to a maximally tolerated dose regimen\n             of gabapentin or pregabalin"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "165", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01893125", 
            "org_study_id": "CNV2197944/202"
        }, 
        "intervention": [
            {
                "arm_group_label": "CNV2197944", 
                "intervention_name": "CNV2197944", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 7, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Gyor", 
                    "country": "Hungary", 
                    "zip": "H-9002"
                }, 
                "name": "Petz Aladar County Teaching Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Hungary"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised Three Week Double-blind Crossover Study to Compare the Efficacy and Safety of CNV2197944 75 mg Tid Versus Placebo in the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy", 
        "overall_contact": {
            "email": "kevin.gunn@convergencepharma.com", 
            "last_name": "Kevin P Gunn, MD", 
            "phone": "+44 1223 755501"
        }, 
        "overall_official": {
            "affiliation": "Dept. Metabolism and Diabetes, Gyor, Hungary", 
            "last_name": "Tibor Hidvegi, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Hungary: National Institute of Pharmacy", 
                "Hungary: Ministry of Health, Social and Family Affairs", 
                "Czech Republic: State Institute for Drug Control", 
                "Romania: National Medicines Agency", 
                "Bulgaria: Bulgarian Drug Agency", 
                "Poland: Ministry of Health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Pain Intensity Numerical Rating Scale", 
            "safety_issue": "No", 
            "time_frame": "21 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01893125"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pain Responder rates", 
                "safety_issue": "No", 
                "time_frame": "21 days"
            }, 
            {
                "measure": "Neuropathic Pain Symptom Inventory", 
                "safety_issue": "No", 
                "time_frame": "21 days"
            }
        ], 
        "source": "Convergence Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Convergence Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}